The Jonathan Jaques Children’s Cancer Center (JJCCC) at Miller Children’s has been heavily involved in research programs involving blood disorders, cancers, psychosocial issues and long-term survival for more than 25 years.
One of Miller Children’s key differentiators is the fact that JJCCC’s participation in clinical research focuses on a multidisciplinary approach to therapy—with expertise in psychology, social work, nutrition, and other supportive care. This translates into JJCCC’s research efforts with clinical, behavioral science and psychosocial research initiatives. JJCCC also is an active participant in the National Hemophilia Registry.
Miller Children’s is considered to be a leading institution for the Children’s Oncology Group (COG). Miller Children’s Hospital consistently exceeds national average in enrollment of patients to clinical trials and in the tumor registry.
In addition to participating in ongoing COG clinical trials on disease and treatment, Miller Children’s Hospital Long Beach participates in national studies on the late effects of childhood cancer treatment and survivorship. Many survivors, depending on their treatment, are at risk for a multitude of chronic and/or late-occurring health problems attributed to their cancer or its treatment.
JJCCC partners with many local hospitals such as Harbor-UCLA, CHLA, Rady Children’s and national consortiums, such as Children’s Oncology Group (COG), National Association of Children’s Hospitals & Related Institutes (NACHRI) and the Hemophilia & Thrombosis Research Society (HTRS).